In prostate cancer cells, Asangani (18) found that EZH2 catalyzes H3K27 trimethylation to inhibit miR-26a, miR-31, and miR-203, which target the 3’-UTR of NSD2. The gene discussed is EZH2; the disease is prostate cancer.